Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
SAN FRANCISCO, April 05, 2018 -- Hagens Berman Sobol Shapiro LLP alerts investors in Solid Biosciences, Inc. (NASDAQ:SLDB) to the May 29, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the District of Massachusetts. If you purchased Solid Biosciences securities pursuant and/or traceable to its January 25, 2018 initial public offering and/or on the open market between January 25, 2018 and March 14, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information, visit:
https://www.hbsslaw.com/cases/SLDB
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing
Defendants conducted an initial public offering of Solid Biosciences on or about January 25, 2018. In this IPO, the Company sold approximately 7 million shares at $16 per share to investors.
On March 15, 2018, Defendants announced the U.S. Food and Drug Administration placed a clinical hold on the Company’s Phase 1/2 trial assessing its SGT-001 drug in patients with Duchenne muscular dystrophy. This news drove the price of Solid Biosciences shares down $16.99, or about 65%, to close at $9.32.
The Motley Fool later reported that just prior to the IPO, a prominent researcher left its board because of risks associated with the drug delivery method for Solid Biosciences’ SGT-001 drug.
“We’re focused on investors’ losses and Defendants’ disclosures about internal concerns over the safety of the SGT-001 delivery method leading up to- and after- the IPO,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Solid Biosciences should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000
